Neutral 340B Edge RxParadigm offers a neutral 340B clearinghouse and a platform (Tungsten+PLUS) that identifies 340B claims, reduces duplicate discounts, ensures compliance, and maintains program integrity, presenting a compelling value proposition for hospitals, health systems, and covered entities seeking streamlined 340B management.

Payer-Manufacturer Link The solution connects Payers, Manufacturers, and Covered Entities, enabling integrated control and visibility across the 340B ecosystem, which can be leveraged to upsell to hospital networks and pharmacy benefit managers seeking end-to-end 340B governance.

Growth Opportunity RxParadigm operates in a market with large, revenue scale players (e.g., Express Scripts, Prime Therapeutics) and a mid-market segment; targeting mid-sized health systems and regional hospitals could yield rapid adoption via partnerships, pilots, or co-marketing with established PBMs.

Recent Partnerships past collaboration with Scipher Medicine indicates openness to ecosystem partnerships and data-enabled offerings, suggesting opportunities to bundle 340B compliance with precision medicine initiatives or payer-driven value programs.

Financial Signals Reported revenue range of one to ten million and a lean employee base (11-50) imply a nimble organization with potential for scalable SaaS/recurring revenue models; sales segments should emphasize modular pricing, quick ROI, and scalable deployment across multi-site health systems.